997 Drug repurposing approaches to fght Dengue virus infection and related diseases Lorenzo Botta 1 , Mirko Rivara 2 , Valentina Zuliani 2 , Marco Radi 2 1 Biological and Ecological Department (DEB), University of Tuscia, 01100 Viterbo, Italy, 2 Department of Food and Drug, University of Parma, Viale delle Scienze, 27/A, 43124 Parma, Italy TABLE OF CONTENTS 1. Abstract 2. Introduction 3. DENV replication and biological targets 4. Drug repurposing for Dengue 4.1. Antiviral drugs 4.1.1. Nelfnavir 4.1.2. Balapiravir 4.1.3. Mycophenolic acid and ribavirin 4.1.4. ZX-2401 4.2. Antimalaric drugs 4.2.1. Chloroquine 4.2.2. Amodiaquine 4.3. Antidiabetic drugs 4.3.1. Castanospermine 4.3.2. Celgosivir 4.3.3. Deoxynojirimycin 4.3.4. CM-10–18 4.4. Antihistamine drugs 4.4.1. Cromolyn, montelukast, ketotifene 4.5. Anticancer drugs 4.5.1. Dasatinib and AZD0530 (Saracatinib) 4.5.2. Bortezomib 4.6. Antipsycotic drugs 4.6.1. Prochlorperazine 4.7. Antiparasite drugs 4.7.1. Ivermectin 4.7.2. Suramin 4.7.3. Nitazoxanide A 4.8. Anticholesteremic drugs 4.8.1. Lovastatin 4.9. Steroid drugs 4.9.1. Dexamethasone 4.9.2. Prednisolone 4.10. Antibiotic drugs 4.10.1. Geneticin 4.10.2. Narasin 4.10.3. Minocycline 4.11. Antiarrhythmic drugs 4.11.1. Lanatoside C 5. Conclusions 6. Acknowledgements 7. References [Frontiers In Bioscience, Landmark, 23, 997-1019, January 1, 2018]